Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

Fragoso, Yara; Spelman, Tim; BOZ, CAVİT; Alroughani, Raed; Lugaresi, Alessandra; Vucic, Steve; Butzkueven, Helmut; TERZİ, MURAT; Havrdova, Eva; Horakova, Dana; Granella, Franco; Olascoaga, Javier; Luis Sanchez-Menoyo, Jose; Pucci, Eugenio; Barnett, Michael; Brooks, Joseph; Haartsen, Jodi

doi:10.1016/j.msard.2017.11.018

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

Atıf İçin Kopyala

Fragoso Y. D., Spelman T., BOZ C., Alroughani R., Lugaresi A., Vucic S., ...Daha Fazla

MULTIPLE SCLEROSIS AND RELATED DISORDERS, cilt.19, ss.105-108, 2018 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 19
Basım Tarihi: 2018
Doi Numarası: 10.1016/j.msard.2017.11.018
Dergi Adı: MULTIPLE SCLEROSIS AND RELATED DISORDERS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.105-108
Anahtar Kelimeler: Fingolimod, Lymphocytes, Multiple sclerosis, Relapses, Disability, MULTIPLE-SCLEROSIS, FTY720
Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Background: Fingolimod is an efficient and safe drug for treating relapsing-remitting multiple sclerosis (RRMS). In vivo, fingolimod is phosphorylated and binds to "sphingosine-1-phosphate"(S1P) receptors that are expressed in a wide range of cells, including lymphocytes. Under the effect of fingolimod, lymphocytes are retained in lymphoid tissues through the regulation of S1P(1) receptors. The aim of the present study was to assess whether the degree of lymphopenia was correlated to the positive treatment response of RRMS patients with fingolimod.